CONDITION

Dilated Cardiomyopathy in Dogs

A condition where the heart muscle weakens and chambers enlarge, reducing the heart's ability to pump blood effectively.

Why this matters now

Dilated cardiomyopathy (DCM) primarily affects large and giant breed dogs, with the condition most commonly diagnosed between four and ten years of age. Breeds with well-established genetic predisposition include Dobermann Pinschers (where the prevalence is particularly high, estimated at 40-60% depending on the population), Great Danes, Irish Wolfhounds, Boxer Dogs, Newfoundlands, Saint Bernards, and Cocker Spaniels (which represent an unusual small-breed exception). Male dogs appear to be affected more commonly and at younger ages than females in many predisposed breeds. In recent years, attention has also focused on a possible association between certain grain-free and legume-rich diets and the development of DCM in breeds not traditionally predisposed, though this relationship remains an active area of investigation and the exact mechanisms and degree of dietary contribution continue to be debated. The condition may develop and progress subclinically for months to years before clinical signs become apparent, meaning that significant cardiac dysfunction may be present before the disease is recognised.

DCM in dogs typically progresses through a prolonged occult (preclinical) phase before manifesting as overt heart failure. During the occult phase, the heart muscle is progressively weakening and the heart chambers are gradually dilating, but compensatory mechanisms — including neurohormonal activation, increased heart rate, and ventricular remodelling — maintain cardiac output near normal levels and the dog shows no outward signs of disease. This occult phase may last for years, during which the disease can only be detected through screening methods such as echocardiography and Holter monitoring. Once compensatory mechanisms are overwhelmed, the transition to overt congestive heart failure can be relatively rapid, with dogs developing signs over days to weeks. In Dobermann Pinschers, the disease course may include a distinctive pattern involving ventricular arrhythmias that can precede the development of systolic dysfunction, and sudden cardiac death may occur before heart failure develops. The rate of progression from occult to overt disease varies between breeds and individuals, influenced by the underlying genetic mutation, the degree of myocardial damage, and concurrent factors.

Signals & patterns

Early signals

Exercise intolerance

A gradual reduction in the dog's willingness or ability to exercise may be one of the earliest noticeable changes, as the compromised heart struggles to increase cardiac output sufficiently to meet the demands of physical activity. Dogs may tire more quickly on walks, lag behind on previously manageable routes, or show reluctance to engage in play or activities they previously enjoyed. This change often develops incrementally, making it easy to attribute to ageing, weight gain, or weather conditions rather than recognising it as a potential cardiac sign. The exercise intolerance reflects the heart's diminishing reserve capacity — its inability to augment output when demands increase.

Subtle respiratory changes

Mildly increased respiratory rate or effort, particularly during rest or sleep, may develop as the heart begins to struggle with maintaining adequate circulation. Owners may notice the dog breathing slightly faster than usual while lying down, or occasional episodes of more laboured breathing after minimal exertion. Sleeping respiratory rate — the number of breaths per minute while the dog is peacefully asleep — can be a sensitive early indicator of developing fluid accumulation in the lungs, with rates consistently above 25-30 breaths per minute in a sleeping dog warranting attention. These respiratory changes may be intermittent initially and can precede the development of overt heart failure by weeks to months.

Intermittent weakness or collapse

Episodes of transient weakness, stumbling, or brief collapse (syncope) may occur, particularly during excitement or exertion, and can be caused by cardiac arrhythmias — particularly ventricular tachycardia — that transiently reduce cardiac output to the brain. In Dobermann Pinschers, syncopal episodes may be the first clinical sign of occult DCM, sometimes occurring before echocardiographic changes are detectable. These episodes are typically brief (seconds to minutes), and the dog may recover rapidly and appear normal between events, which can lead to them being dismissed as isolated incidents rather than recognised as potential indicators of underlying cardiac disease.

Reduced appetite and weight changes

Some dogs in the early stages of DCM may show a subtle decrease in appetite or gradual weight loss, reflecting the metabolic demands of the compensating cardiovascular system and early subclinical congestion. Conversely, fluid retention may initially manifest as weight gain despite reduced appetite, as sodium and water retention increase blood volume. These changes tend to be gradual and may not be immediately attributed to cardiac disease, particularly in breeds where weight fluctuation is not uncommon.

Cardiac arrhythmias detected incidentally

In some dogs, the first indication of occult DCM may be the detection of an irregular heart rhythm during a routine veterinary examination or a procedure requiring auscultation. Ventricular premature complexes (VPCs) — extra heartbeats originating from the ventricles — are particularly common in DCM and may be heard as irregular beats or pulse deficits during physical examination. In predisposed breeds, the incidental finding of arrhythmias during routine veterinary visits may prompt further cardiac investigation that reveals occult disease.

Later signals

Coughing and respiratory distress

As DCM progresses to left-sided congestive heart failure, fluid accumulates in the lungs (pulmonary oedema), producing a cough that may initially be soft and intermittent but can progress to persistent, productive coughing and increasing respiratory difficulty. The cough may be most noticeable at night or during rest, when the recumbent position allows fluid to redistribute within the lungs. In severe cases, the dog may show open-mouth breathing, reluctance to lie down (orthopnoea), and visible respiratory effort with exaggerated chest and abdominal movements. The transition from mild coughing to significant respiratory distress can occur rapidly, sometimes over a period of hours.

Abdominal distension (ascites)

Right-sided or biventricular heart failure can lead to the accumulation of fluid in the abdominal cavity (ascites), producing a progressively distended abdomen that may develop over days to weeks. The ascites results from increased venous pressure in the systemic circulation causing fluid to leak from the blood vessels into the peritoneal space. The abdominal distension may be accompanied by reduced appetite (as the fluid compresses abdominal organs) and difficulty breathing (as the distended abdomen pushes against the diaphragm). In large and giant breed dogs with DCM, significant volumes of ascitic fluid can accumulate before it becomes externally obvious.

Profound lethargy and weakness

As cardiac output declines further in advanced DCM, dogs may show marked lethargy, reluctance to move, weakness during standing or walking, and a general disengagement from their surroundings and normal activities. The reduced cardiac output means that insufficient blood reaches the muscles, brain, and other organs to support normal function. Dogs may seek cool, quiet locations, show prolonged recovery after any activity, and may be reluctant to eat or drink due to the combined effects of reduced perfusion, congestion, and general malaise.

Sudden death

In some dogs with DCM — particularly Dobermann Pinschers — sudden cardiac death may occur without preceding clinical signs of heart failure, caused by fatal ventricular arrhythmias (ventricular tachycardia degenerating into ventricular fibrillation). This devastating outcome can occur during any phase of the disease, including the occult phase when no outward signs of cardiac disease are apparent. The risk of sudden death is a significant feature of DCM in certain breeds and is one of the primary motivations for screening programmes in predisposed populations, as early detection and antiarrhythmic therapy may reduce this risk.

Click to read about the biological mechanisms

How this is usually investigated

Investigation of DCM involves a combination of cardiac imaging, electrocardiography, biomarker analysis, and sometimes genetic testing. The approach differs somewhat depending on whether the dog is being screened for occult disease (in a predisposed breed) or being evaluated for suspected overt heart failure.

Echocardiography

Purpose: Echocardiography (cardiac ultrasound) is the primary diagnostic tool for DCM, providing real-time visualisation of the heart's structure and function. The examination measures chamber dimensions (identifying ventricular dilation), assesses myocardial contractility (identifying reduced systolic function through measurements such as fractional shortening and ejection fraction), evaluates valve function (identifying secondary mitral regurgitation), and can detect pericardial or pleural effusion. In screening for occult disease, serial echocardiographic measurements over time can detect progressive chamber enlargement and declining function before clinical signs develop.
Considerations: Echocardiography requires specialised equipment and expertise in cardiac imaging, typically available through veterinary cardiologists or experienced practitioners. Breed-specific reference ranges for chamber dimensions and functional parameters are important, as normal values vary considerably between different sized dogs. A single echocardiogram provides a snapshot of cardiac status at that point; serial examinations over time provide more valuable information about the trajectory of the disease. In some dogs with arrhythmic DCM (particularly Dobermanns), echocardiographic changes may lag behind the development of arrhythmias, meaning a normal echocardiogram does not necessarily exclude early occult disease.

Electrocardiography (ECG) and Holter monitoring

Purpose: A standard ECG provides information about heart rhythm, rate, and electrical conduction at the time of recording, and may reveal ventricular premature complexes, atrial fibrillation, or other arrhythmias associated with DCM. Holter monitoring — continuous 24-hour ambulatory ECG recording — is considerably more sensitive for detecting intermittent arrhythmias and is a critical component of DCM screening in predisposed breeds, particularly Dobermann Pinschers where ventricular arrhythmias may be the first manifestation of occult disease. Holter monitoring can quantify the frequency and complexity of ventricular ectopy, which has prognostic significance and guides decisions about antiarrhythmic therapy.
Considerations: Standard ECGs capture only a few minutes of cardiac rhythm and may miss intermittent arrhythmias that occur at other times — a dog may have thousands of VPCs per day that happen to be absent during the brief recording period. Holter monitoring overcomes this limitation but requires the dog to wear the recording device for 24 hours, which some dogs tolerate better than others. Interpretation of Holter results requires expertise, and breed-specific thresholds for abnormal VPC frequency vary (in Dobermanns, more than approximately 50-100 VPCs in 24 hours is often considered concerning). Access to Holter monitoring may be limited outside specialist cardiology services.

Cardiac biomarkers

Purpose: Blood-based cardiac biomarkers — primarily cardiac troponin I (cTnI) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) — can provide supportive diagnostic information and screening data. Cardiac troponin I is released into the bloodstream when cardiomyocytes are damaged or dying, and elevated levels may indicate active myocardial injury. NT-proBNP is released in response to myocardial wall stress and volume overload, and elevated levels correlate with the severity of cardiac chamber enlargement and dysfunction. Both biomarkers can be used as screening tools in predisposed breeds, with elevated levels prompting more detailed cardiac investigation.
Considerations: Cardiac biomarkers are sensitive but not specific to DCM — elevations can occur with other forms of cardiac disease, non-cardiac illness, and even intense exercise. Normal biomarker levels do not definitively exclude occult DCM, as the disease may not have progressed to the point of detectable myocardial stress or damage. Biomarkers are most valuable as part of a multi-modal screening approach (combined with echocardiography and Holter monitoring) rather than as standalone diagnostic tests. Serial biomarker measurements over time may be more informative than single readings, as trends can indicate disease progression before absolute values exceed reference ranges.

Thoracic radiography

Purpose: Chest radiographs provide information about heart size and shape, pulmonary vasculature, and the presence of pulmonary oedema or pleural effusion. In dogs with overt DCM, radiographs typically reveal generalised cardiomegaly (enlarged heart silhouette), distended pulmonary veins, and patterns of pulmonary oedema indicating left-sided heart failure. Radiographs can help distinguish cardiac causes of respiratory signs from non-cardiac causes and are valuable for monitoring the response to heart failure treatment. The vertebral heart score (VHS) — a standardised measurement of heart size relative to vertebral body length — provides an objective assessment that can be tracked over time.
Considerations: Thoracic radiography is less sensitive than echocardiography for detecting early or occult DCM, as significant cardiac dysfunction may be present before the heart silhouette appears obviously enlarged on radiographs. Radiographic assessment of heart size can be influenced by patient positioning, respiratory phase, and body conformation. In breeds with deep-chested conformations (such as Dobermanns), the normal heart silhouette may appear relatively small, potentially masking early enlargement. Radiographs are most valuable in the context of overt heart failure rather than occult disease screening.

Genetic testing

Purpose: Genetic tests are available for some of the identified mutations associated with DCM in specific breeds, most notably the PDK4 and titin mutations in Dobermann Pinschers. These tests can identify dogs carrying one or two copies of the mutations, providing information about genetic risk that may inform breeding decisions and screening programmes. Identifying at-risk dogs through genetic testing allows targeted screening with echocardiography and Holter monitoring to begin at an appropriate age.
Considerations: Available genetic tests cover only a subset of the mutations that contribute to DCM, and a negative test result does not guarantee that a dog will not develop the condition, as additional undiscovered genetic factors may be involved. Conversely, a positive test indicates increased risk but does not confirm that the dog will develop clinical disease, as penetrance (the proportion of carriers that actually develop the condition) varies. Genetic testing is currently most established for Dobermann Pinschers, and the genetic basis of DCM in many other predisposed breeds remains incompletely characterised. The tests are most useful as one component of a comprehensive approach to breed health that includes clinical screening.

Options & trade-offs

Management of DCM involves a combination of medical therapies aimed at supporting cardiac function, managing fluid accumulation, controlling arrhythmias, and slowing disease progression. The treatment approach varies between the occult and overt phases of the disease, and is tailored to the individual dog's clinical presentation and response.

Pimobendan (positive inotrope and vasodilator)

Pimobendan is a phosphodiesterase III inhibitor and calcium sensitiser that increases the force of cardiac contraction while simultaneously dilating blood vessels, thereby improving cardiac output while reducing the workload on the heart. It has become a central component of DCM management in both the occult and overt phases, with landmark studies (particularly the PROTECT trial in Dobermanns) demonstrating that pimobendan significantly delays the onset of heart failure when started during the occult phase. In overt heart failure, pimobendan improves clinical signs, quality of life, and survival time when combined with other heart failure medications.

Trade-offs: Pimobendan is generally well tolerated, though it can theoretically increase the risk of certain arrhythmias by increasing intracellular calcium levels, which requires consideration in dogs that already have significant ventricular ectopy. The medication is administered orally, typically twice daily on an empty stomach (at least one hour before feeding), which requires consistent owner compliance. The cost of long-term pimobendan therapy varies by region and dog size. In dogs with occult DCM, the decision about when to initiate pimobendan requires balancing the demonstrated benefits of early intervention against the commitment to lifelong medication in a dog that currently shows no clinical signs.

ACE inhibitors and neurohormonal modulation

Angiotensin-converting enzyme (ACE) inhibitors (such as benazepril, enalapril, or ramipril) reduce the activity of the renin-angiotensin-aldosterone system, lowering blood pressure, reducing cardiac workload, and counteracting the deleterious effects of chronic neurohormonal activation on the myocardium. These medications are commonly used in conjunction with pimobendan in both occult and overt DCM. Spironolactone, an aldosterone antagonist, may be added for its additional neurohormonal modulating and mild diuretic effects, with evidence suggesting that it may provide survival benefits in heart failure patients.

Trade-offs: ACE inhibitors require monitoring of kidney function and electrolytes, particularly during initiation and dose adjustments, as they can reduce glomerular filtration pressure and occasionally cause or exacerbate azotaemia. The medications are generally well tolerated but can cause gastrointestinal upset, hypotension, or reduced appetite in some dogs. The evidence for ACE inhibitor monotherapy in occult DCM (without pimobendan) is less compelling than for pimobendan, leading to their more common use as adjunctive therapy. Multiple daily medications require owner organisation and commitment to consistent administration.

Diuretic therapy

Furosemide (frusemide) and other loop diuretics are essential for managing fluid accumulation in dogs with overt congestive heart failure. By promoting sodium and water excretion through the kidneys, diuretics reduce pulmonary oedema, ascites, and pleural effusion, thereby alleviating respiratory distress and improving comfort. The dose is titrated to the minimum effective level that controls fluid accumulation, as excessive diuresis can lead to dehydration, electrolyte imbalances, and kidney injury. In cases of diuretic resistance (where standard doses no longer adequately control fluid), additional diuretics with different mechanisms of action (such as hydrochlorothiazide or spironolactone) may be combined in a 'diuretic stacking' approach.

Trade-offs: Diuretic therapy requires careful balance — insufficient dosing leaves the dog congested and uncomfortable, while excessive dosing causes dehydration, electrolyte depletion (particularly potassium), and can compromise kidney function. Regular monitoring of kidney values and electrolytes is essential, particularly during dose adjustments. Increased urination is an expected effect that can affect the dog's daily routine and overnight comfort, potentially requiring more frequent outdoor access. Diuretic requirements often increase over time as the disease progresses, and progressive diuretic resistance can become a limiting factor in long-term heart failure management.

Antiarrhythmic therapy

Dogs with significant ventricular arrhythmias associated with DCM may require antiarrhythmic medications to reduce the frequency and complexity of ectopic beats and decrease the risk of sudden cardiac death. Sotalol, a beta-blocker with additional class III antiarrhythmic properties, is commonly used for ventricular arrhythmias in dogs with DCM, though mexiletine, amiodarone, and other agents may be used alone or in combination depending on the arrhythmia type and response. The decision to initiate antiarrhythmic therapy is guided by the frequency, complexity, and clinical impact of the arrhythmias, typically assessed through Holter monitoring.

Trade-offs: Antiarrhythmic drugs can have pro-arrhythmic effects (paradoxically worsening arrhythmias in some cases), and their use requires careful dose titration and monitoring. Beta-blockers such as sotalol reduce heart rate and contractility, which can worsen heart failure signs in dogs with already compromised systolic function — requiring careful balancing of the antiarrhythmic benefits against potential negative effects on cardiac output. Holter monitoring before and after starting antiarrhythmic therapy helps assess efficacy and detect adverse effects. Some antiarrhythmic medications require monitoring of organ function, and drug interactions with other cardiac medications must be considered.

Nutritional supplementation and dietary considerations

Nutritional support may include supplementation with omega-3 fatty acids (which have anti-inflammatory and antiarrhythmic properties), taurine and L-carnitine (particularly in breeds or cases where deficiency may contribute to the cardiomyopathy), and coenzyme Q10 (an antioxidant involved in mitochondrial energy production). In cases potentially associated with diet-related DCM, transitioning to a diet meeting conventional nutritional profiles may be recommended. Sodium restriction in dogs with heart failure helps reduce fluid retention, though the degree of restriction varies and excessively severe sodium restriction is generally unnecessary with modern pharmacological management.

Trade-offs: The evidence base for individual nutritional supplements in canine DCM varies, with some having stronger support than others. Taurine supplementation may be beneficial in breeds or individuals with documented taurine deficiency (such as Cocker Spaniels or dogs fed certain diets), but may not provide benefit in dogs with normal taurine levels. The cost of multiple supplements accumulates, and palatability issues may arise. Dietary changes should be implemented carefully in dogs with heart failure, as appetite may already be reduced and nutritional adequacy is important for maintaining body condition and cardiac muscle mass. The relationship between grain-free diets and DCM remains an area of ongoing investigation, and definitive guidance on this topic continues to evolve.

Common misconceptions

Misconception:

"DCM only affects Dobermann Pinschers and is not a concern for other breeds."

Reality:

While Dobermann Pinschers have one of the highest prevalences of DCM and are among the most studied breeds for this condition, DCM affects a wide range of large and giant breeds including Great Danes, Irish Wolfhounds, Newfoundlands, Saint Bernards, Boxers, and several others. Cocker Spaniels represent a notable small-breed exception where a form of DCM associated with taurine deficiency has been documented. The genetic basis, clinical presentation, and disease progression may differ between breeds — for example, Boxers often present with an arrhythmogenic form, while Irish Wolfhounds may show a more gradual decline in systolic function. The recent attention to possible diet-associated DCM has further expanded the range of breeds in which the condition may be encountered.

Misconception:

"If a dog shows no symptoms, there is no need to screen for DCM."

Reality:

The prolonged occult phase of DCM — during which significant cardiac dysfunction develops without external signs — is precisely why screening in predisposed breeds can be valuable. In Dobermann Pinschers, studies have shown that initiating treatment with pimobendan during the occult phase significantly delays the onset of heart failure and prolongs survival compared to waiting until clinical signs appear. Similarly, detecting and treating significant arrhythmias during the occult phase may reduce the risk of sudden cardiac death. Screening protocols typically recommend annual echocardiography and Holter monitoring beginning at age three to four in high-risk breeds, though the specifics vary by breed and individual risk factors.

Misconception:

"Once a dog develops heart failure from DCM, nothing meaningful can be done."

Reality:

While DCM-related heart failure is a serious and ultimately progressive condition, medical management can significantly improve quality of life, alleviate symptoms, and extend survival time in many dogs. The combination of pimobendan, ACE inhibitors, diuretics, and other therapies has substantially improved outcomes compared to earlier eras of treatment. Many dogs with well-managed heart failure can maintain good quality of life for months, and some for a year or more after the onset of clinical signs. The management requires ongoing monitoring and dose adjustments, but the period of comfortable, active life that effective treatment can provide is meaningful. The goal of treatment shifts from preventing the disease to maintaining comfort, function, and quality of life for as long as possible.

Dilated cardiomyopathy represents a condition where understanding the progression from the occult to the overt phase provides valuable context for the different stages of the management journey. In predisposed breeds, awareness of the breed-specific patterns — including the age of typical onset, the nature of the preclinical phase, and the potential for sudden events — contributes to a more informed perspective. The ongoing research into genetic markers, dietary associations, and novel therapeutic approaches continues to evolve the understanding of this condition, and the relationship between early detection, timely intervention, and clinical outcomes remains an important area of veterinary cardiology.

Last reviewed: 24 April 2026 · Dr Alastair Greenway MRCVS